Moreover, the combination of RXR and PPARγ agonists, bexarotene and rosiglitazone respectively, inhibited cell growth by suppressing COX-2 and PGE2 while increasing carcinoembryonic antigen (CEA) in Moser CRC cells. This evidence concerns the gene PTGS2 and colorectal carcinoma.